
    
      to evaluate the efficacy and safety of zoledronic acid by measuring changes in bone turnover
      markers

        -  the incidence of skeletal-related events

        -  time to skeletal-related events

        -  time to bone metastases progression

        -  overall survival

        -  the incidence of each adverse event including osteonecrosis
    
  